Daily Archives: September 16, 2019

Wilmington Trust and Nasdaq Fund Network Provide First Publicly Searchable Ticker Symbols for Collective Investment Trusts (CITs)

Wilmington Trust registers over 200 CITs with Nasdaq Fund Network, increasing information access and transparency for investors

NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) and Wilmington Trust today announced the first-ever tickers for Collective Investment Trusts (“CITs”) on Nasdaq Fund Network (NFN). NFN is a global dissemination service whose mission is to bring greater retail investment transparency to the world’s financial markets. NFN and Wilmington Trust, a leader in institutional trust services, have collaborated to provide searchable tickers for more than 200 CITs. CITs are low-cost investment vehicles similar in structure to mutual funds, but available only to 401(k) and other qualified retirement plans. NFN now enables investors to easily access information on these low-cost investment funds with a standardized ticker for the first time.

Nasdaq Fund Network and Wilmington Trust solve a major obstacle to CIT adoption: the lack of standardized ticker symbols. The market can now access CIT price and performance information across many market data platforms, and provide advisors, broker dealers, and investors with easy access to much-needed daily net asset value information.

CITs provide lower-cost fee options similar to separately managed accounts, with not only the operational and processing conveniences of a mutual fund, but also with flexibility to accommodate hedge funds, private equity, and other alternative investments, which in recent years have played a larger role in defined contribution and defined benefit plans. CITs generally have lower legal, marketing, board and compliance-related costs, and plan fees than mutual funds. Operational efficiency is another benefit, as CITs are traded through the National Securities Clearing Corporation (NSCC), which mirrors the mutual fund structure.

“It is more important than ever for our clients to understand the various investment vehicles and make informed choices,” said Christopher Randall, Head of Retirement and Institutional Custody Services at Wilmington Trust. “As the first institution to register CITs with Nasdaq Fund Network, we are helping overcome a major challenge to widespread adoption of CITs, providing the information advisors, plan sponsors, and participants need to make fully informed decisions.”

“Since its founding, Nasdaq has been providing greater market transparency, the cornerstone of fair and open markets,” said Lauren Dillard, Executive Vice President and Head of Nasdaq’s Global Information Services. “Our collaboration with Wilmington Trust to register CITs on Nasdaq Fund Network is a significant advancement in our mission to provide a much fuller and robust view of the financial markets.”

Wilmington Trust is a leader in the CIT market with over $46 billion in assets across funds managed by more than 50 sub-advisors, and available on more than 35 trading platforms. As a fiduciary, Wilmington Trust collaborates with more than two dozen industry partners. Wilmington Trust recently joined with both AllianceBernstein and Federated Investors to offer CITs. Today, investors can enjoy the benefits of CIT Nasdaq Fund Network registration.

Nasdaq Fund Network (NFN) registers and distributes performance data for 35,000-plus investable products to one million plus investors on a daily basis. NFN provides the global investing public daily access to valuations for registered financial instruments, including mutual funds, money market funds, unit investment trusts (UITs), annuities, Separately Managed Accounts/Unified Managed Accounts, collective investment trusts, alternative investments, and structured products.

About Nasdaq: 
Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information, and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize, and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 100 marketplaces in 50 countries. Nasdaq is home to over 4,000 total listings with a market value of approximately $14 trillion. To learn more, visit business.nasdaq.com.

About Wilmington Trust
Wilmington Trust, N.A. provides corporate and institution services including institutional trustee, retirement plan, agency, asset management, and administrative services for clients worldwide who use capital markets financing structures. Wilmington Trust provides directed trustee, custody, and fiduciary services for retirement plans, companies, foundations, organizations, and financial institutions.

Wilmington Trust also provides Wealth Advisory services with a wide array of personal trust, financial planning, fiduciary, asset management, and family office solutions designed to help high-net-worth individuals and families grow, preserve and transfer wealth.

Wilmington Trust maintains offices throughout the United States and internationally in London, Paris, Dublin, and Frankfurt. For more information, visit www.WilmingtonTrust.com.

Disclosure: Collective Funds Wilmington Trust N.A. Collective Portfolios (“WTNA Portfolios”) are trust company-sponsored collective portfolios; they are not mutual funds. The WTNA Portfolios and units therein are exempt from registration under the Securities Act of 1933, as amended, and the Investment Company Act of 1940. Investments in the WTNA Portfolios are not deposits or obligations of or guaranteed by Wilmington Trust, and are not insured by the FDIC, the Federal Reserve, or any other governmental agency. The Portfolios are commingled investment vehicles, and as such, the values of the underlying investments will rise and fall according to market activity; it is possible to lose money by investing in the Portfolios. Participation in Collective Investment Trust Funds is limited primarily to qualified defined contribution plans and certain state or local government plans. Collective Investment Trust Funds may also be suitable investments for participants seeking to construct a well-diversified retirement savings program. Investors should consider the investment objectives, risks, charges and expenses of any pooled investment company carefully before investing.

Nasdaq Media Contact:
Matthew Sheahan
(212) 231-5945
matthew.sheahan@nasdaq.com

Wilmington Trust Media Contact:
Maya Dillon
(212) 415-0557
mdillon@wilmingtontrust.com

 

CP Kelco Expands LMA Pectin Production by 15% to Address Global Market Demand

ATLANTA, Sept. 16, 2019 (GLOBE NEWSWIRE) — CP Kelco, a global leader of nature-based ingredient solutions, announced today that it will increase pectin production capacity by about 15 percent at its Lille Skensved, Denmark, facility in response to continued global demand for the product. This significant investment will enhance market supply in 2020 of low methoxyl amidated (LMA) pectin, which is suited for products such as ambient drinking yogurts and fruit preparations.

“Two converging megatrends are driving the demand for pectin: the consumers’ increased desire for dairy and plant-based protein products, and a continued drive towards better-for-you, clean label foods and beverages,” said Susanne Sörgel, Senior Director, Pectin Platform Strategy at CP Kelco. “As a result, the global pectin market is experiencing significant growth and we predict this will continue. This capacity investment at our Denmark plant will strengthen our ability to meet the evolving needs and growth aspirations of our customers worldwide.”

In March 2019, CP Kelco also announced an investment to expand pectin production capacity at its Limeira, Brazil, facility by approximately 10 percent. “With this further expansion of pectin capacity to come online in 2020, we are demonstrating our ongoing commitment to provide a sustainable supply of this important nature-based ingredient into the future,” added Luiz Azzolino, Senior Director, Food Gums Operations at CP Kelco.

Derived from citrus peels, CP Kelco’s GENU® Pectin is a multifunctional, label-friendly ingredient that serves as a stabilizer and texturizing agent in jams and jellies, yogurts, acidified protein beverages, dairy desserts and more. The GENU Pectin portfolio includes products that meet non-GMO, vegan and organic compliance requirements. CP Kelco is the world’s leading pectin producer, operating production facilities in Limeira, Brazil, Lille Skensved, Denmark and Groβenbrode, Germany.

About CP Kelco

CP Kelco is a nature-based ingredient solutions company with over 85 years of experience working with food, beverage and consumer products manufacturers worldwide. We unlock nature-powered success by applying ingredient innovation and problem solving to develop customized solutions that leverage our regional insights and meet manufacturers’ goals to address consumer needs and preferences.  What sets us apart:

  • Unique Portfolio. Produces extensive range of high-quality, plant-based and fermentation-derived ingredients to formulate tailored solutions.
  • Technical Excellence. Offers strong collaboration with a global team of scientists and applications experts, leveraging our regional state-of-the art R&D facilities.
  • Sustainability. Committed to providing responsibly sourced and produced ingredients.
  • Market Insights. Understands market and consumer trends to help customers create relevant and innovative products.

Our key product lines include gellan gum, pectin, xanthan gum, carrageenan, diutan gum, cellulose gum/CMC, refined locust bean gum, microparticulated whey protein concentrate and our latest innovations, CELLULON Cellulose Liquid (fermentation derived cellulose) and NUTRAVA™ Citrus Fiber. Learn more at www.cpkelco.com.

CONTACT: 
Michele Cacdac-Jones
Director, Brand & Marketing Communications 
michele.cacdac-jones@cpkelco.com 
Mobile: +1 770 743 0564

CP Kelco Expands LMA Pectin Production by 15% to Address Global Market Demand

ATLANTA, Sept. 16, 2019 (GLOBE NEWSWIRE) — CP Kelco, a global leader of nature-based ingredient solutions, announced today that it will increase pectin production capacity by about 15 percent at its Lille Skensved, Denmark, facility in response to continued global demand for the product. This significant investment will enhance market supply in 2020 of low methoxyl amidated (LMA) pectin, which is suited for products such as ambient drinking yogurts and fruit preparations.

“Two converging megatrends are driving the demand for pectin: the consumers’ increased desire for dairy and plant-based protein products, and a continued drive towards better-for-you, clean label foods and beverages,” said Susanne Sörgel, Senior Director, Pectin Platform Strategy at CP Kelco. “As a result, the global pectin market is experiencing significant growth and we predict this will continue. This capacity investment at our Denmark plant will strengthen our ability to meet the evolving needs and growth aspirations of our customers worldwide.”

In March 2019, CP Kelco also announced an investment to expand pectin production capacity at its Limeira, Brazil, facility by approximately 10 percent. “With this further expansion of pectin capacity to come online in 2020, we are demonstrating our ongoing commitment to provide a sustainable supply of this important nature-based ingredient into the future,” added Luiz Azzolino, Senior Director, Food Gums Operations at CP Kelco.

Derived from citrus peels, CP Kelco’s GENU® Pectin is a multifunctional, label-friendly ingredient that serves as a stabilizer and texturizing agent in jams and jellies, yogurts, acidified protein beverages, dairy desserts and more. The GENU Pectin portfolio includes products that meet non-GMO, vegan and organic compliance requirements. CP Kelco is the world’s leading pectin producer, operating production facilities in Limeira, Brazil, Lille Skensved, Denmark and Groβenbrode, Germany.

About CP Kelco

CP Kelco is a nature-based ingredient solutions company with over 85 years of experience working with food, beverage and consumer products manufacturers worldwide. We unlock nature-powered success by applying ingredient innovation and problem solving to develop customized solutions that leverage our regional insights and meet manufacturers’ goals to address consumer needs and preferences.  What sets us apart:

  • Unique Portfolio. Produces extensive range of high-quality, plant-based and fermentation-derived ingredients to formulate tailored solutions.
  • Technical Excellence. Offers strong collaboration with a global team of scientists and applications experts, leveraging our regional state-of-the art R&D facilities.
  • Sustainability. Committed to providing responsibly sourced and produced ingredients.
  • Market Insights. Understands market and consumer trends to help customers create relevant and innovative products.

Our key product lines include gellan gum, pectin, xanthan gum, carrageenan, diutan gum, cellulose gum/CMC, refined locust bean gum, microparticulated whey protein concentrate and our latest innovations, CELLULON Cellulose Liquid (fermentation derived cellulose) and NUTRAVA™ Citrus Fiber. Learn more at www.cpkelco.com.

CONTACT: 
Michele Cacdac-Jones
Director, Brand & Marketing Communications 
michele.cacdac-jones@cpkelco.com 
Mobile: +1 770 743 0564

The Boiling Crab ประกาศการทำข้อตกลงสิทธิ์แฟรนไชส์ระดับนานาชาติครั้งที่สอง

GARDEN GROVE, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) — The Boiling Crab® ที่มีชื่อเสียงในด้านการให้บริการอาหารทะเลสดๆ และทานง่ายในบรรยากาศที่เป็นกันเอง ได้ทำข้อตกลงสิทธิ์แฟรนไชส์ระดับนานาชาติครั้งที่สอง ข้อตกลงใหม่นี้เกิดขึ้นกับ Full Feeling Global, Inc. ที่ตั้งอยู่ในกรุงมะนิลา และครอบคลุมสาธารณรัฐฟิลิปปินส์ (ฟิลิปปินส์) ซึ่งเป็นตลาดที่มีความสำคัญเชิงกลยุทธ์

The Boiling Crab® ก่อตั้งขึ้นในปี 2004 โดยมุ่งเน้นว่าทุกคนควรสามารถเพลิดเพลินไปกับรสชาติของอาหารทะเลสดๆ รสชาติเยี่ยม และประสบการณ์ที่น่าจดจำในการแบ่งปันปูต้มที่สวนหลังบ้านกับเพื่อนๆ “ผ้ากันเปื้อน เบียร์ ขาปู และบริษัทที่ดีนี่แหละคือตัวตนของเรา” กล่าวโดย Dada Ngo ผู้บริหารสูงสุด

ด้วยสาขาทั้งหมด 21 แห่งทั่วสหรัฐอเมริกา รวมถึงแคลิฟอร์เนีย เท็กซัส เนวาดา ฮาวาย และฟลอริดา และเซี่ยงไฮ้ ประเทศจีนก็เป็นสาขาต่างประเทศแห่งแรกที่เปิดในช่วงปลายปี 2019 ซึ่งการขยายตลาดสู่ฟิลิปปินส์ก็เป็นการเพิ่มเอเชียตะวันออกเฉียงใต้ลงในผลงานที่กำลังเติบโตของ The Boiling Crab®

“เรารู้สึกตื่นเต้นมากในการขยายสาขาไปยังฟิลิปปินส์ซึ่งเป็นประเทศที่มีหลักการเดียวกับแนวคิดของเรา นั่นคือความรักในการแบ่งปันอาหารกับครอบครัวและเพื่อนฝูงที่ดีทุกคน พร้อมกับการรับประทานอาหารด้วยมือ ซึ่งสำหรับ The Boiling Crab® นี่คือสิ่งที่บ่งบอกว่าเรายังคงเผยแพร่ความรักของอาหารทะเลสดที่มีอยู่ทั่วโลก และเชิญผู้คนเข้ามาในครอบครัวของเรามากขึ้น” Ngo กล่าวเสริม

ข้อตกลงการอนุญาตให้ใช้สิทธิ์ของฟิลิปปินส์จะทำให้เกิดการเปิดร้านอาหารแห่งแรกในกรุงมะนิลาในต้นปี 2020 โดยจะมีร้านอาหารอีก 7 แห่งที่จะเปิดให้บริการในฟิลิปปินส์ภายในปี 2024 Full Feeling Global, Inc. เป็นผู้ดำเนินการแฟรนไชส์ที่ประสบความสำเร็จด้วยคอนเซ็ปต์อาหารฟาสต์ฟู้ดยอดนิยมอย่าง Jollibees และ Dohtonburi อีกหลากหลายแห่ง ร้านอาหาร Dohtonburi เป็นแฟรนไชส์จากประเทศญี่ปุ่นที่เชี่ยวชาญในการผลิตแพนเค้กแสนอร่อยอย่างโอโคโนมิยากิ ซึ่งเป็นร้านแฟรนไชส์แห่งแรกนอกประเทศญี่ปุ่น พิสูจน์ให้เห็นถึงความสามารถของ Full Feeling Global ในการนำเสนอร้านอาหารใหม่ๆ ในตลาดฟิลิปปินส์

ข้อตกลงใบอนุญาตเพิ่มเติมในประเทศอื่นๆ ในเอเชียแปซิฟิกอยู่ในระหว่างการเจรจา

เกี่ยวกับ THE BOILING CRAB®

The Boiling Crab® เป็นร้านอาหารที่เหมาะสำหรับครอบครัวที่มีความเชี่ยวชาญในอาหารทะเล Cajun แบบลุยเซียนา เมนูประกอบด้วยกุ้งน้ำจืด กุ้ง ปู และหอยต่างๆ รวมถึงเมนูอย่าง ปลาดุกทอด กระเจี๊ยบ มันฝรั่งทอด Cajun และเครื่องดื่มแอลกอฮอล์และไม่มีแอลกอฮอล์ให้เลือกมากมาย

The Boiling Crab® สาขาแรกเปิดในปี 2004 ใน Garden Grove รัฐแคลิฟอร์เนีย และเป็นที่นิยมในวัฒนธรรมอาหารทะเลต้มแบบ Cajun ที่ได้รับแรงบันดาลใจจากรัฐลุยเซียนาพร้อมทั้งรสชาติดั้งเดิมอันเป็นเอกลักษณ์ของ The Whole Shabang®

ติดต่อด้านสื่อ

Winnie Vu
winnie@theboilingcrab.com
โทร: 714.554.6181
FAX: 714.489.8115

Batavia Biosciences receives $6.5M grant to take next step towards polio-free world

Leiden, the Netherlands, Sep 16, 2019 – Today, Batavia Biosciences announces it received a grant of $6.5 million from the Bill & Melinda Gates Foundation to develop a manufacturing process for a novel oral vaccine against polio virus type 2 strain (nOPV2) to help protect children worldwide from future polio outbreaks.

In a collaboration with PATH and Bio Farma, one of the world’s leading OPV manufacturers, Batavia Biosciences is currently producing attenuated and safe novel oral polio vaccine (nOPV) candidates in its Good Manufacturing Practices (GMP) facility. The nOPV2 vaccine to be developed under the grant from the Bill & Melinda Gates Foundation is the first nOPV vaccine to go through clinical development, to be followed by vaccines for nOPV1 and nOPV3.

Chris Yallop, CSO of Batavia Biosciences, explains: “The nOPV2 vaccine, provided by our partner Bio Farma, is currently the most advanced in clinical development and most in demand. The successful development of a low-cost manufacturing process for the novel PV2 strain will allow us to next apply our developed process to the novel PV1 and PV3 strains.”

The manufacturing process for the nOPV2 vaccine is based on the same highly intensified, low-cost vaccine manufacturing platform that Batavia Biosciences developed together with Univercells for the inactivated Sabin polio vaccine (sIPV). The platform combines Univercells NevoLine™ manufacturing technology with Batavia Biosciences’ Highly Intensified Process (HIP-Vax) technology for viral vaccines.

Menzo Havenga, CEO of Batavia Biosciences, comments: “We are very excited to work with these eminent partners and take the next step towards a polio-free world. Only by working closely together will we be able to protect every last child from all forms of poliovirus.”

About Batavia Biosciences
Batavia Biosciences significantly contributes to ease human suffering from infectious diseases by improving the success rate in the translation of candidate medicines from discovery to the clinic. We offer our novel technologies and in-depth know-how in order to help our partners to complete preclinical phases in biopharmaceutical product development at higher speed, reduced costs and increased success. The company focuses on the early stages of product development including cell line generation, upstream process development (mammalian & microbial), purification development, product characterization and clinical manufacturing. Headquartered in Leiden, the Netherlands, with a subsidiary in Woburn, Massachusetts, and offices in Hong Kong, Batavia Biosciences is privileged to have strong strategic partners worldwide.

www.bataviabiosciences.com

About Bio Farma
Supported by competent employees with experience for more than 125 years, Bio Farma, a state-owned enterprise in Indonesia, manufacturing and distributing vaccines and one of a few WHO pre-qualified vaccine manufacturers, plays an important role in fostering a healthy community, both national as well as global. With the philosophy “Dedicated to improve Quality of Life”, Bio Farma strives to devote efforts to Global Health Security. Bio Farma focuses on research and development, manufacture, marketing and distribution of biological products both nationally and globally. Bio Farma plays an active role in advancing vaccine and other life science products among others through research collaboration among prominent partners both national as well as international.  For more information on Bio Farma please visit:

www.biofarma.co.id

Contact for editors
Claire Otjes, Marketing Manager
c.otjes@bataviabiosciences.com
+31889950600